Oral News and Research

RSS

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Researchers find that an experimental anticlotting pill Eliquis is more effective than standard drug, warfarin, at preventing strokes in people with a heart condition that puts them at high risk of blood clots and stroke. The new drug also known as apixaban, cut the risk of stroke by 21% compared with warfarin in people with atrial fibrillation (AF). It lowered the risk of dying by 11%.

30 Aug 2011

Affinium closes $15 million financing round

Affinium Pharmaceuticals announced today the closing of its $15 million financing. Investors participating in the financing include all three of Affinium's Series A investors, SV Life Sciences, Genesis Capital Partners and Forward Ventures, along with the addition of the Ontario Emerging Technologies Fund (OETF) to the syndicate.

29 Aug 2011

Post myocardial infarction snus quitters have 44% lower risk of mortality

In this prospective cohort study, presented today at the ESC Congress 2011, discontinuation of smokeless tobacco after a myocardial infarction (MI) is associated with a lower risk of subsequent mortality. Investigators found that post MI snus quitters had a 44 % lower risk of total mortality.

29 Aug 2011

Study shows feasibility of combined postprandial glucose and triglyceride tolerance testing

The Homburg Cream and Sugar (HCS) study was designed to determine whether the measurement of postprandial triglyceride in addition to the assessment of glucose tolerance and traditional risk factors might improve the prediction of cardiovascular events.

29 Aug 2011

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

New data from two RE-LY trial sub-group analyses show that dabigatran etexilate provides consistent benefits in stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil.

29 Aug 2011

Post MI snus quitters have lower risk of mortality

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

Astellas seeks regulatory approval for mirabegron to treat overactive bladder in the U.S., Europe

Astellas Pharma Inc. today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron to the U.S. Food and Drug Administration and the European Medicines Agency.

29 Aug 2011

Apixaban superior to warfarin in preventing stroke and systemic embolism

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation.

29 Aug 2011

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

29 Aug 2011

FDA tips for tackling hurricanes

The FDA reminds consumers to take precautions for storing water and ensuring the safety of their food and medical supplies for themselves and their pets during and after this week's expected hurricane-related rain, possible flooding and power outages.

26 Aug 2011

BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.

26 Aug 2011

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.

26 Aug 2011

Allergan gets FDA nod for use of Botox in urinary incontinence

Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.

25 Aug 2011

AHF shares The Lancet's concerns over use of Gilead's Truvada as HIV prevention pill

Today AIDS Healthcare Foundation (AHF) commented on an editorial published in the September 2011 issue of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment drug Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis (PrEP), agreeing with the publication's public health concerns.

25 Aug 2011

Baxter enters definitive agreement to acquire Baxa

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire Baxa Corporation, a privately held company based in Englewood, Colo., with additional operations in Florida and the United Kingdom.

From Baxter International Inc. 25 Aug 2011

OHA, Plackers announce five winners of Smiles Across America Innovation Grants

Plackers, makers of the first disposable dental flosser, and Oral Health America (OHA), a national, charitable non-profit, announced five winners of the first-ever Smiles Across America Innovation Grants, each of whom will receive monetary grants to kick-start innovative new programs intended to deliver oral health preventative products and services to children at increased risk for oral diseases.

25 Aug 2011

Health law legal challenges: Date set for oral arguments in the 8th Circuit Court of Appeals

Missouri's health reform lawsuit is heading for oral arguments in the 8th Circuit Court of Appeals. The 8th Circuit on Tuesday said oral arguments in the lawsuit, which challenges the individual mandate and the Medicaid expansion, will take place in St. Paul, Minn., during the week of Oct. 17.

25 Aug 2011

USPTO issues Notice of Allowance for Cortex AMPAKINE molecules to treat respiratory depression

Cortex Pharmaceuticals, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent that protects the use of AMPAKINE molecules for the treatment or prevention of respiratory depression.

25 Aug 2011

IMMY, University of Nevada receive FDA clearance for CrAg Lateral Flow Assay

The Food and Drug Administration has cleared a new diagnostic test that will help save the lives of hundreds of thousands of AIDS patients stricken with cryptococcosis, a fungal meningitis.

25 Aug 2011

Oral News and Research

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Affinium closes $15 million financing round

Post myocardial infarction snus quitters have 44% lower risk of mortality

Study shows feasibility of combined postprandial glucose and triglyceride tolerance testing

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

Post MI snus quitters have lower risk of mortality

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

Astellas seeks regulatory approval for mirabegron to treat overactive bladder in the U.S., Europe

Apixaban superior to warfarin in preventing stroke and systemic embolism

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

FDA tips for tackling hurricanes

BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Allergan gets FDA nod for use of Botox in urinary incontinence

AHF shares The Lancet's concerns over use of Gilead's Truvada as HIV prevention pill

Baxter enters definitive agreement to acquire Baxa

OHA, Plackers announce five winners of Smiles Across America Innovation Grants

Health law legal challenges: Date set for oral arguments in the 8th Circuit Court of Appeals

USPTO issues Notice of Allowance for Cortex AMPAKINE molecules to treat respiratory depression

IMMY, University of Nevada receive FDA clearance for CrAg Lateral Flow Assay

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News